目的 :观察必思添改善慢性阻塞性肺疾病反复下呼吸道感染的疗效。方法 :慢性阻塞性肺疾病反复下呼吸道急性感染的病人 64例 ,随机分成必思添加抗生素治疗组 33例 (男性 2 5例 ,女性 8例 ,年龄 70a±s13a) ,服抗生素基础上加服必思添mo1,2mg·d- 1,mo 2～ 3,1mg·d- 1,每月服 8d ,单服抗生素治疗为对照组 31例 (男性 2 5例 ,女性 6例 ,年龄 72a± 12a)。观察随访 2组病人用药后 6mo内临床状况。结果 :治疗组病人下呼吸道急性感染发作次数显著减少 ,感染持续时间明显缩短 ,抗生素的用量显著减少 ,且无副作用。结论 :必思添是改善慢性阻塞性肺疾病下呼吸道感染的安全和有效药物 OBJECTIVE: To observe the effect of Biseth to improve recurrent lower respiratory tract infection in chronic obstructive pulmonary disease. Methods: Sixty-four patients with chronic obstructive pulmonary disease (COPD) with acute lower respiratory tract infection were randomly divided into 33 cases (25 males and 8 females, age 70a ± s13a) treated with antibiotics plus antibiotics, Tim Tim mo1,2mg · d-1, mo2 ~ 3,1mg · d-1, 8d monthly, single-agent antibiotics treatment for the control group of 31 patients (25 males and 6 females, age 72a ± 12a) . Follow up 2 groups of patients after treatment within 6 months of clinical conditions. Results: In the treatment group, the frequency of acute respiratory infection in the lower respiratory tract was significantly reduced, the duration of infection was significantly shortened, the dosage of antibiotics was significantly reduced, and no side effects were observed. CONCLUSIONS: Bismuth is a safe and effective drug for the treatment of lower respiratory tract infections in chronic obstructive pulmonary disease